Based on a hypothetical scenario positing 100 percent accuracy in test results, we examined interest in genetic testing for Alzheimer's disease (AD) among adult children, 40-60 years of age, who have a living parent with a diagnosis of probable AD (N = 108), and a matched comparison group of persons with no parental history of AD (N = 150). For both groups, planning for the future was the most important reason cited for being tested; lack of good treatment options and concerns about losing health insurance were the most important reasons for not being tested. Hierarchical regression was used to examine the effects of sociodemographic characteristics, subjective perceptions of memory functioning, concerns about having and developing AD, and mastery on interest in being tested. Personal concerns about developing AD and mastery emerged as significant predictors and subsample membership approached significance, although the full model explained just 18 percent of the variance. Because persons in the comparison group were more likely to report an interest in being tested, educational efforts about genetic testing should not be restricted only to family members of persons with a diagnosis of AD.
Sobel SK, Cowan DB: Impact of genetic testing for Huntington disease on the family system. Am J Med Genet. 2000; 90: 49-59.
2.
Blacker D, Tanzi RE: The genetics of Alzheimer disease. Arch Neurol. 1998; 55: 294-296.
3.
Ganguli M, Chandra V, Kamboh MI, et al.: Apolipoprotein E polymorphism and Alzheimer disease. Arch Neurol. 2000; 57: 824-830.
4.
Green RC, Cupples LA, Go, R, et al.: Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002; 287: 329-336.
5.
Codori A, Brandt J: Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet. 1994; 54: 174-184.
6.
Craufurd D, Dodge A, Kerzin-Storrar L, Harris R: Uptake of presymptomatic predictive testing for Huntington's disease. The Lancet. 1989; II: 603-605.
7.
Quaid KA, Brandt J, Folstein SE: The decision to be tested for Huntington's disease. JAMA. 1987; 257: 3362-3362.
8.
Wiggins S, Whyte P, Huggins M, et al.: The psychological consequences of predictive testing for Huntington's disease. N Engl J Med. 1992; 327: 1401-1405.
9.
Almqvist EW, Bloch M, Brinkman R, et al: A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet. 1999; 64: 1293-1304.
10.
Meiser B, Dunn S: Psychological impact of genetic testing for Huntington's disease: An update of the literature. J Neurol Neurosurg Psychiatr. 2000; 69: 574-578.
11.
Chaliki H, Loader S, Levenkron JC, et al.: Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health. 1995; 85: 1133-1135.
12.
Lerman C, Daly M, Masny A, et al.: Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncology. 1994; 12: 843-850.
13.
Struewing JP, Lerman C, Kase RG, et al.: Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev. 1995; 4: 169-173.
14.
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CTM, et al.: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000; 355: 2015-2020.
15.
Broadstock M, Michie S, Marteau T: Psychological consequences of predictive genetic testing: A systematic review. Eur J Hum Genet. 2000; 8: 731-738.
16.
Lerman C, Narod S, Schulman K, et al.: BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes. JAMA. 1996; 275: 1885-1892.
17.
Green RC, Clarke VC, Thompson NJ, et al.: Early detection of Alzheimer disease: Methods, markers, and misgivings. Alzheimer Dis Assoc Disord. 1997; 11: S1-S5.
18.
Long Island Alzheimer's Foundation: Gene Survey Results. LIAF Line1996; January: 1-2.
19.
Neumann PJ, Hammitt JK, Mueller C, et al.: Public attitudes about genetic testing for Alzheimer's disease. Health Affairs. 2001; 20(5): 252-264.
20.
Roberts JS: Anticipating response to predictive genetic testing for Alzheimer's disease: A survey of first-degree relatives. Gerontologist. 2000; 40: 43-52.
21.
AGS Ethics Committee: Genetic testing for late-onset Alzheimer's disease. J Am Geriatr Soc. 2001; 49: 225-226.
22.
Post SG, Whitehouse PJ, Binstock RH, et al.: The clinical introduction of genetic testing for Alzheimer disease. JAMA. 1997; 277: 832-836.
23.
Steinbart EJ, Smith CO, Poorkaj P, et al.: Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001; 58: 1828-1831.
24.
Lerman C, Seay J, Balshem A, et al: Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 1995; 57: 385-392.
25.
Marteau TM, Croyle RT: Psychological responses to genetic testing. British Medical Journal. 1998; 316: 693-696.
26.
Mastromauro C, Myers RH, Berkman, B: Attitudes toward presymptomatic testing in Huntington disease. Am J Med Genet. 1987; 26: 271-282.
27.
Codori A, Hanson R, Brandt J: Self-selection in predictive testing for Huntington's disease. Am J Med Genet. 1994; 54: 167-173.
28.
Quaid KA, Morris M: Reluctance to undergo predictive testing: The case of Huntington disease. Am J Med Genet. 1993; 45: 41-45.
29.
Tambor ES, Bernhardt BA, Chase GA, et al.: Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet. 1994; 55: 626-637.
30.
Silverman JM, Li G, Zaccario ML, et al.: Patterns of risk in firstdegree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry. 1994; 51: 577-586.
31.
Kahneman D, Tversky A: The psychology of preferences. Sci Am. 1982; 246: 160-173.
32.
Cutler SJ, Hodgson LG: Anticipatory dementia: A link between memory appraisals and concerns about developing Alzheimer's disease. Gerontologist. 1996; 36: 657-664.
33.
Cutler SJ, Hodgson LG: Correlates of personal concerns about developing Alzheimer's disease among middle-aged persons. Am J Alzheimer's Dis Other Demen. 2001; 16: 335-343.
34.
Herrmann D: Questionnaires about memory. In: Harrie J, Morris P (eds.): Everyday Memory, Actions, and Absentmindedness. New York: Academic Press, 1984, 133-151.
35.
Hodgson LG, Cutler SJ, Livingston K: Alzheimer's disease and symptom-seeking. Am J Alzheimers Dis. 1999; 14: 364-373.
36.
Wexler NS: Genetic “Russian roulette”: The experience of being “at risk” for Huntington's disease. In: Kessler S (ed): Genetic Counseling: Psychological Dimensions. New York: Academic Press, 1979: 199-220.
37.
Mirowsky J: Age, subjective life expectancy, and the sense of control: The horizon hypothesis. J Gerontol B Psychol Sci Soc Sci. 1997; 52B: S125-S134.
38.
Pearlin L, Lieberman M, Menaghan E, et al: The stress process. J Health Soc Behav. 1981; 22: 337-356.
39.
Singer E, Corning A, Lamias M: The polls-trends: Genetic testing, engineering, and therapy. Public Opinion Quarterly. 1998; 62: 633-664.
40.
Hodgson LG, Cutler SJ: Anticipatory dementia and well-being. Am J Alzheimers Dis. 1997; 12: 62-66.
41.
Verhaeghen P, Geraerts N, Marcoen A: Memory complaints, coping, and well-being in old age: A systemic approach. Gerontologist. 2000; 40: 540-548.
42.
Codori A, Slavney PR, Young C, et al: Predictors of psychological adjustment to genetic testing for Huntington's disease. Health Psychology. 1997; 16: 36-50.
43.
Miller SM, Mangan CE: Interacting effects of information and coping style in adapting to gynecologic stress: Should the doctor tell all?J Personality Soc Psychol. 1983; 45: 223-236.
44.
Wallace KA, Bergeman CS: Control and the elderly: “Goodnessoffie”. Int J Aging Hum Dev. 1997; 45: 323-339.
45.
Chipperfield JG, Greenslade L: Perceived control as a buffer in the use of health care services. J Gerontol B Psychol Sci Soc Sci. 1999; 54B: P146-P154.
46.
Coon DW, Davies H, McKibben C, et al: The psychological impact of genetic testing for Alzheimer disease. Genet Test. 1999; 3: 121-131.
47.
Murphy DJ, Gahm GJ, Santilli S, et al.: Seniors' preferences for cancer screening and medication use based on absolute risk reduction. J Gerontol A Biol Sci Med Sci. 2002; 57A: M100-M105.
48.
Aranda MP: Racial and ethnic factors in dementia care-giving research in the US. Aging & Mental Health. 2001; 5: S116-S123.
49.
Connell CM, Shaw BA, Holmes SB, et al: Caregivers' attitudes toward their family members' participation in Alzheimer disease research: Implications for recruitment and retention. Alzheimer Dis Assoc Disord. 2001; 15: 137-145.
50.
Roberts JS, Connell CM: Illness representations among firstdegree relatives of people with Alzheimer disease. Alzheimer Dis Associated Disord. 2000; 14: 129-136.
51.
Tarlow BA, Mahoney DF: The cost of recruiting Alzheimer's disease caregivers for research. J Aging & Health. 2000; 12: 490-510.
52.
Quaid KA: Implications of genetic susceptibility testing with apolipoprotein E. In: Post S, Whitehouse P (eds.): Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues. Baltimore: Johns Hopkins University Press, 1998, 118-139.
